31 results about "Increase muscle mass" patented technology

This invention relates to the field of biotechnology, and more particularly to a swelling-promoting seahorse oil and its application in the preparation of anti-sarcopenia products. Obtained using a supercritical carbon dioxide extraction process, the swelling-promoting seahorse oil of this invention has been experimentally verified to inhibit muscle degradation, promote muscle cell activation and differentiation, increase muscle mass, and enhance muscle strength and endurance. Furthermore, it exerts its effects through dietary supplementation with no significant adverse reactions, and can be used to prepare anti-sarcopenia related foods, health products, or pharmaceuticals to meet the muscle health maintenance needs of the elderly.

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

It was confirmed that probiotic metabolites of the present invention protect muscle cells and promote differentiation of muscle fibers. In addition, it was confirmed in an animal model of muscle atrophy or sarcopenia induced by dexamethasone that probiotic metabolites increased muscle mass and muscle function, inhibited expression of factors associated with muscle degradation, and increased expression of factors associated with muscle synthesis and regeneration. It was confirmed that probiotic metabolites contribute to alleviation of muscle atrophy by regulating sugar, amino acid, and fatty acid metabolism altered by dexamethasone.

The present invention provides a composition and method for increasing muscle mass, preventing muscle atrophy, and promoting muscle growth. [Solution] In certain aspects, the disclosed composition comprises dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, the disclosed composition is administered to subjects in need to increase muscle mass, prevent muscle atrophy, and / or promote muscle growth.

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and / or agents which lead to increased muscle mass.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

The present invention relates to the use of a hemp seed extract for preventing or ameliorating muscle diseases by promoting myoblast differentiation or muscle regeneration. In the present invention, the hemp seed extract may exhibit preventive or therapeutic effects on various muscle diseases by increasing muscle mass, strengthening muscle power, improving muscle function, and enhancing exercise performance, and also has an effect of improving muscle function in healthy individuals in addition to treating muscle diseases.

This application relates to animals or cells possessing a myostatin gene, wherein 12 base pairs of the second exon of the myostatin gene are deleted. This application may also include compositions capable of manipulating the deletion of 12 base pairs of the myostatin gene to construct animals or cells. This application also relates to the use of this composition for increasing muscle mass.

The present invention relates to a composition for increasing muscle mass, improving muscle function, or preventing or treating muscle disease, comprising Phocaeicola vulgatus or cultures thereof. In addition, the present invention relates to a method for increasing muscle mass, improving muscle function,, or preventing or treating muscular disease, comprising administering or taking a composition comprising Phocaeicola vulgatus or a culture thereof as an active ingredient to an individual in need. The Phocaeicola vulgatus of the present invention has the outstanding effect of increasing muscle strength, increasing muscle weight, and increasing muscle fiber.

The present invention provides a polypeptide consisting of the sequence of SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and / or treatment of a muscle disease or disorder. The present invention also provides a nucleic acid sequence encoding the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the present invention may be administered in the form of a pharmaceutical composition, together with at least one pharmaceutically acceptable excipient, diluent, or carrier. The present invention also provides non-therapeutic methods for improving muscle function and / or increasing muscle mass in a subject.

The invention provides novel antibodies that bind to activin type IIB receptor (ActRITB), or activin type IIA receptor (ActRIIa) or both. The antibodies block ligand binding to the receptors and modulate downstream signaling. The invention also provides novel compositions and methods for treating a metabolic disorder, improving glycemic control, promoting increased muscle mass, and reducing adipose tissue and treating osteoarthritis. The methods and compositions are used to treat type 2 diabetes.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.

Myogenic compounds identified in egg yolk and synthetic derivatives thereof, nutraceutical compositions of one or more of these myogenic compounds and synthetic derivatives thereof and use of these compounds and nutraceutical compositions in increasing muscle mass in mammals are provided.

To provide compounds to increase muscle mass, muscle oxidative capacity, and muscle function and to treat muscular dystrophy, in particular limb girdle muscular dystrophy type 2A / R1 / D1, compositions including the compounds, and treatment methods.SOLUTION: The present invention provides a compound having the chemical structure of formula (I), and a composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof.SELECTED DRAWING: None

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.

The present invention relates to a composition for enhancing exercise performance, increasing muscle mass, improving muscle function, or preventing or treating muscular disease, comprising Polygonum multiflorum Thunberg extract. The extract of the present invention has the effect of enhancing muscle strength, increasing muscle mass, improving exercise performance, and the like.

To provide a Lactobacillus paracasei NB23 strain and its uses for increasing muscle mass and preventing metabolic syndrome.SOLUTION: The present invention discloses a Lactobacillus paracasei NB23 strain and its uses for increasing muscle mass and preventing metabolic syndrome. The Lactobacillus paracasei NB23 strain is deposited at the Food Industry Research and Development Institute in Hsinchu City, Taiwan, under the deposit number BCRC911201. By administering the Lactobacillus paracasei NB23 strain or a metabolite thereof to an individual, the effect of effectively treating or preventing diseases associated with muscle loss or insufficient muscle mass, metabolic syndrome, and diseases related thereto can be achieved.SELECTED DRAWING: Figure 1

This invention belongs to the field of nutritional supplement technology, specifically relating to a hemp seed dietary fiber composition, its products, and applications. The composition comprises hemp seed dietary fiber; based on the total weight of the raw materials (100%), the hemp seed dietary fiber accounts for 10% to 50% of the total weight. This invention uses hemp seed, a food and medicine homology source, as the active ingredient in the composition, ensuring high safety. This composition achieves synergistic effects through multiple mechanisms, including improving gut health, regulating glucose and lipid metabolism, and modulating the FFAR2-RYR-MYOG pathway. It can significantly improve muscle function and increase muscle mass, effectively preventing and improving sarcopenia. It is particularly suitable for the elderly and those intolerant to high-protein diets or with insulin resistance, solving the problems of limited effectiveness, low compliance, and high safety risks associated with existing intervention methods.

The present invention relates to compositions and methods for altering body composition in an individual, wherein the alteration in body composition is both an increase in muscle mass and a decrease in fat mass. The present invention also relates to compositions and methods for decreasing fat mass in an individual. The compositions and methods also increase muscle volume and lean body mass in an individual. The present invention also relates to compositions comprising a GDF8 inhibitor and an activin A inhibitor, and the use of such compositions to treat diseases and conditions characterized by increased fat mass and / or decreased muscle volume.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

The present invention relates to a composition for preventing, alleviating or treating sarcopenia, containing D-ribo-2-hexulose as an active ingredient. D-ribo-2-hexulose of the present invention is a sweetener capable of replacing sugar, is harmless to the human body and does not cause side effects in normal cells so as to be safe for the human body, inhibits the degradation of myoproteins, and can exhibit muscle strengthening effects by increasing muscle mass, and thus the present invention is expected to be effectively usable in the prevention, alleviation or treatment of sarcopenia.

This disclosure provides myostatin and activin A peptide immunogen constructs, compositions and methods for their use in, for example, maintaining and improving muscle physiology (e.g., increasing muscle mass, strength, function, tone or endurance), preventing and treating muscular or musculoskeletal injury, preventing and treating a disorder associated with muscle loss or insufficient muscle growth, and / or preventing and treating muscle wasting diseases.

The present invention relates to a composition for increasing muscle mass, improving muscle function, or preventing or treating muscle disease, comprising micheliolide or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for increasing muscle mass, improving muscle function, or preventing or treating muscular disease, comprising administering or taking a composition comprising micheliolide or a pharmaceutically acceptable salt thereof as an active ingredient to an individual in need. The micheliolide of the present invention has the outstanding effect of increasing muscle strength, increasing muscle weight, and increasing muscle fiber.

The present invention relates to a composition for ameliorating and treating a muscle disease and cachexia, which includes diflunisal. The diflunisal has an effect of promoting the differentiation and proliferation of myoblast cells, and also has an effect of ameliorating and treating cachexia caused by muscle diseases or chronic diseases such as cancer through effects such as increasing muscle mass, recovering muscle strength, and the like.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 1 of the myostatin gene and is capable of inhibiting the production of the mRNA of the myostatin gene. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and / or hypertrophy, an agent for increasing muscle mass and / or inhibiting muscle weakness, an agent for inhibiting production of the mRNA of the myostatin gene, and an inhibitor of the function of myostatin, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

This invention provides the use of OICR-9429 or a pharmaceutically acceptable salt thereof in the preparation of products for improving age-related indications. The OICR-9429 provided by this invention exhibits multiple beneficial technical effects in improving age-related indications, effectively alleviating the inflammatory response caused by pyroptosis during aging, and improving the immune function and anti-infection ability of aging organisms. OICR-9429 also has a significant therapeutic effect on sepsis, inhibiting the rise in inflammation levels caused by infection, improving the survival rate and prognosis of elderly patients. Long-term intervention with OICR-9429 can continuously reduce the chronic inflammatory state of aging organisms, increase muscle mass, enhance motor ability, prolong life, and reduce the occurrence of various age-related diseases. This invention lays the foundation for the development of products that comprehensively intervene in aging and related functional decline, and has important application value in improving the quality of life of the elderly.

The present invention belongs to the field of medicine technology, and specifically relates to the use of poly (L-lactide) and / or a copolymer comprising L-lactic acid repeating units or microspheres thereof, or a composition comprising poly (L-lactide) and / or a copolymer comprising L-lactic acid repeating units or microspheres thereof in the preparation of a drug for preventing and treating obesity and metabolic complications caused by obesity. In an embodiment, the composition further comprises at least one GPR81 agonist. The poly (L-lactide) and / or the copolymer comprising L-lactic acid repeating units, the microspheres thereof, or the composition comprising the same provided by the present invention are capable of preventing the fat and / or body weight of a subject from increasing while maintaining muscle mass, have good effects of reducing weight, increasing muscle mass and regulating glycolipid metabolism, and have no side effects. It can be administered once every few months, which improves patient compliance and provides a new strategy for the treatment of obesity and complications caused by obesity.

The invention provides an application of a dandelion water extract in preparation of a composition for improving muscle mass and skin moisture content, the dandelion water extract is obtained by extracting dandelion with a solvent, and the solvent is water. The dandelion water extract is further used for reducing the expression quantity of PPARG2 gene, C / EBP-alpha gene and GLUT4 gene and increasing the expression quantity of UCP1 gene and CETP gene so as to achieve the effects of reducing fat accumulation, promoting cholesterol metabolism, increasing muscle mass and promoting aquaporin generation.

A probiotic metabolite of the present invention was found to protect muscle cells and promote differentiation of muscle fibers. In addition, the probiotic metabolite was found to increase muscle mass and muscle function, inhibit the expression of muscle degradation-related factors, and increase the expression of muscle synthesis-and regeneration-related factors in a dexamethasone-induced muscular atrophy or sarcopenia animal model. In addition, the probiotic metabolite was found to increase muscle function, protect against damage to muscle tissue, inhibit the expression of factors related to muscle degradation, and increase the expression of factors related to muscle synthesis and regeneration in a fasting-induced muscular atrophy or sarcopenia animal model.

The present technology comprises methods of treating, preventing, reducing, or otherwise ameliorating one or more symptoms or conditions that may benefit from weight gain or a reduction in weight loss. The methods comprise administering a non-naturally occurring melanocortin analog of the present technology to a subject in need thereof. The methods may promote fat gain (e.g., epididymal fat or perirenal fat), increase muscle mass, increase body weight, accelerate weight gain, increase fat mass to lean mass ratio, improve body composition and / or BMI (e.g., for underweight conditions), increase waist circumference, increase cardiac mass, increase brain mass, or any combination thereof, relative to a control.